Moteur de recherche d’entreprises européennes
Financement de l’UE (5 839 656 €) : InSilc: In-silico trials for drug-eluting BVS design, development and evaluation Hor01/11/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
InSilc: In-silico trials for drug-eluting BVS design, development and evaluation
The aim of InSilc is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), by building on the comprehensive biological and biomedical knowledge and advanced modelling approaches to simulate their implantation performance in the individual cardiovascular physiology. The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for simulating the drug-eluting BVS mechanical behaviour, the deployment and degradation, the fluid dynamics in the micro- and macroscale, and the myocardial perfusion, for predicting its interaction with the vascular wall in the short- and medium/long term. InSilc goes beyond the design and development of ISCT and lays on the generation of in-silico models for obtaining quick and informed answers to several “What if” scenarios. “Virtual” patients would be given a “virtual” drug-eluting BVS, for observing the performance of the scaffold, assess and quantify the intended effect, with a deeper understanding than normal trials can provide. By integrating the information obtained from different in-silico predictive models, InSilc will: (i) assist in the development, assessment and optimization of the drug-eluting BVS and deliver accurate and reliable information to the Stent Biomedical Industry, (ii) assist the interventional Cardiologists in improving the surgical process of drug-eluting BVS implantation, support them in the clinical assessment and reduce the complications of suboptimal scaffold performance. By introducing computer simulations for establishing the safety and efficacy of drug-eluting BVS, InSilc aims to lower development costs and shorten time-to-market, reduce, refine, and partially replace human clinical trials through a more effective human clinical trials design, reduce the need for animal testing and result in a significant reduction of the associated direct and indirect costs.
| Boston Scientific Ltd. | 305 580 € |
| CBSET Inc. | 503 212 € |
| Consiglio Nazionale Delle Ricerche | 343 705 € |
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | 805 580 € |
| Feops N.V. | 409 330 € |
| Idryma Technologias Kai Erevnas | 822 366 € |
| Istrazivacko Razvojni Centar ZA Bioinzenjering Bioirc d.o.o. | 363 080 € |
| Mediolanum Cardio Research Srl | 259 330 € |
| Panepistimio Ioanninon | 200 605 € |
| Politecnico Di Milano | 603 130 € |
| The University of Sheffield | 98 000 € |
| University of Galway | 566 155 € |
| University of Leeds | 559 580 € |
https://cordis.europa.eu/project/id/777119
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.